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ABSTRACT
Brahma related gene product 1 (BRG1) is an ATPase that drives the catalytic 
activity of a subset of the mammalian SWI/SNF chromatin remodeling enzymes. BRG1 
is overexpressed in most human breast cancer tumors without evidence of mutation 
and is required for breast cancer cell proliferation. We demonstrate that knockdown 
of BRG1 sensitized triple negative breast cancer cells to chemotherapeutic drugs 
used to treat breast cancer. An inhibitor of the BRG1 bromodomain had no effect on 
breast cancer cell viability, but an inhibitory molecule that targets the BRG1 ATPase 
activity recapitulated the increased drug efficacy observed in the presence of BRG1 
knockdown. We further demonstrate that inhibition of BRG1 ATPase activity blocks 
the induction of ABC transporter genes by these chemotherapeutic drugs and that 
BRG1 binds to ABC transporter gene promoters. This inhibition increased intracellular 
concentrations of the drugs, providing a likely mechanism for the increased 
chemosensitivity. Since ABC transporters and their induction by chemotherapy drugs 
are a major cause of chemoresistance and treatment failure, these results support 
the idea that targeting the enzymatic activity of BRG1 would be an effective adjuvant 
therapy for breast cancer.
INTRODUCTION
Drugs that target genomically defined vulnerabilities 
in human tumors have been effective cancer therapies 
for decades [1]. The specificity of cancer drugs has 
progressively improved, from general cytotoxic agents 
such as nitrogen mustard in the 1940s [2] to natural-
product anticancer drugs such as Vinca alkaloids and 
anthracyclines in the 1960s [3], to specific monoclonal 
antibodies [4], immunotoxins [5], and small molecules 
targeting cell surface receptors and growth-promoting 
signal transduction pathways [6]. Increased specificity 
has improved patient response rates while reducing the 
side effects of anticancer treatment. However, the rapid 
acquisition of resistance to drug treatments remains 
a substantial challenge to the clinical management of 
advanced cancers. Resistance to single drugs can be 
overcome by combinatorial treatment with drugs acting 
via different mechanisms, but cancer cells often evolve 
simultaneous resistance to different structurally and 
functionally unrelated drugs, a phenomenon known 
as multidrug resistance (MDR) [7, 8]. Resistance to 
anticancer drugs arises by various mechanisms and 
especially by the genetic instability of tumor cells driving 
heterogeneity. While therapies have become more targeted 
and effective, acquired resistance has remained the 
principal basis for treatment failure [9, 10].
One common reason for resistance to multiple 
anticancer drugs is the increased expression of one or 
more energy-dependent transporters that result in efflux 
of the drugs from cells [11, 12]. The first identification of 
a molecular mechanism of multidrug resistance was the 
identification of an energy-dependent drug efflux pump, 
known as P-glycoprotein (P-gp) or MDR1, the multidrug 
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transporter [13, 14]. The product of the human MDR1 
gene [15] and the products of two different but related 
mouse genes, Mdr1a and Mdr1b [16, 17], were among 
the first described members of a large family of ATP-
dependent transporters known as the ATP-binding cassette 
(ABC) family [18]. From the 48 known ABC transporters 
[19], members of three subfamilies are important for drug 
efflux from cells: (i) MDR1 P-glycoprotein (ABCB1) from 
the “B” subfamily, which was the first identified ABC 
drug efflux transporter and has been the most completely 
characterized [11]; (ii) several multidrug resistance related 
protein (MRP) transporters from the “C” subfamily 
(ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC10, 
ABCC11) [20-22] and (iii) ABCG2/BCRP from the “G” 
subfamily [23]. 
The SWI/SNF enzymes control gene expression 
through ATP-dependent remodeling of chromatin. 
Mammalian SWI/SNF complexes contain mutually 
exclusive ATPase subunits, either BRM (SMARCA2), 
or BRG1 (SMARCA4) [24-26]. SWI/SNF complexes 
containing BRG1 control cell proliferation, cell lineage 
differentiation and maintain cell pluripotency during 
early embryonic development [27-33]. A growing body 
of evidence suggests that BRG1 exhibits both tumor 
suppressing and tumor promoting functions, depending 
on the type of cancer [32]. Results published by us and 
by others demonstrate that the SWI/SNF ATPases BRG1 
and BRM are up-regulated in primary breast cancer 
and are required for cancer cell proliferation in vitro 
and in vivo [27, 33]. These results suggest that BRG1, 
as a driver of proliferation, could be a drugable target 
in certain cancer types. In addition, BRG1 promotes 
chemoresistance in lung cancer cells [34], where BRG1 
wildtype tumors upregulate BRG1 in response to EZH2 
inhibitor and become more resistant to TOPOII inhibitor. 
In pancreatic tumors, BRG1 knockdown effectively 
reverses chemoresistance to gemcitabine [35]. 
Breast cancer is the most common cancer in women 
and one of the leading causes of cancer death for women, 
with triple negative breast cancer being the most invasive 
and life threatening [36-39]. Triple negative breast cancer 
has been shown to be highly glycolytic, metastatic, and 
chemotherapy resistant; currently there are no standard 
of care effective targeted therapies to combat triple 
negative breast cancer. Therefore, both early stage 
and advanced triple negative breast cancer tumors are 
treated with predominantly cytotoxic chemotherapy. We 
previously reported that reduction of BRG1 results in 
slow proliferation in triple negative breast cancer cells in 
vitro and in xenografts [33]. We report here that depletion 
of BRG1 or an inhibitor targeting the BRG1 ATPase 
domain sensitized triple negative breast cancer cells to 
chemotherapeutic drugs. BRG1 inhibition prevented 
chemotherapy drug-mediated induction of genes encoding 
specific ABC transporter proteins. We conclude that 
targeting the ATPase domain of BRG1, in combination 
with other chemotherapy drugs, is a promising strategy 
for breast cancer treatment.
RESULTS
Breast tumors are heterogeneous with subtypes 
defined by pathology [40] and gene expression profiles 
[41]. Since we were studying chemotherapy drug efflux,we 
chose to focus on the subtype with the most resistance to 
those drugs, the most treatment failures, and the worst 
prognosis for patients [36]. These ‘triple negative’ tumors 
lack estrogen receptor α, lack the progesterone receptor, 
and do not have HER2 upregulation. 
BRG1 depletion sensitized triple negative breast 
cancer cells to chemotherapy drugs
We tested the efficacy of six chemotherapy drugs 
on MDA-MB-231 cells expressing doxycyline-inducible 
shRNA targeting BRG1. Doxorubicin, 5-fluorouracil 
(5-FU), gemcitabine, cisplatin, cyclophosphamide, and 
paclitaxel are used clinically for treating breast cancer 
patients. Doxorubicin induces DNA double-strand 
breaks. 5-FU and gemcitabine are nucleoside analogs. 
Cisplatin crosslinks DNA, while cyclophosphamide 
alkylates and crosslinks DNA. Paclitaxel prevents normal 
breakdown of microtubules during mitosis. These drugs 
are structurally unrelated and have different mechanisms 
of action. Reduction of BRG1 expression significantly 
improved the efficacy of each of these drugs (Figure 1A-
1F, Supplemental Figure 1A) as judged by cell viability 
in MTS assays [42]. The IC50 values were decreased 4 
to 10 fold, supporting the concept that BRG1 reduction 
or inhibition might be effective as an adjunct to currently 
used chemotherapies.
A BRG1 ATPase domain inhibitor decreased 
breast cancer cell proliferation
Only two BRG1 inhibitors have been reported. PFI-
3, or (2E)-1-(2-hydroxyphenyl)-3-[(1R,4R)-5-(pyridin-2-
yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]prop-2-en-1-one, a 
small molecule inhibitor that specifically targets the bromo 
domains of BRG1, BRM, and PB1, is a Pfizer/ Structural 
Genomics Consortium candidate with in vitro potency 
in isothermal titration calorimetry at < 100 nM dose 
(http://www.thesgc.org/chemical-probes/PFI-3; [43, 44]). 
Previously, we reported that depletion of BRG1 in triple 
negative breast cancer cell lines reduced cell proliferation 
[33]. We treated three triple negative breast cancer cell 
lines, MDA-MB-231, MDA-MB-468, and HDQ-P1, with 
PFI-3 at different doses. No inhibition of cell proliferation 
was observed, even at the 10 μM dose as measured by 
MTT assay [45] (Figure 2A). This is consistent with 
recent results demonstrating that PFI-3 did not affect the 
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Figure 1: Reduction of BRG1 levels increased the chemosensitivity of triple-negative breast cancer cells. BRG1 
knockdown was induced by Doxycycline in MDA-MB-231 cells engineered as previously described [33]. Cells were plated in 96-well 
plates with increasing doses of cisplatin A., cyclophosphamide B., doxorubicin C., gemcitabine D., paclitaxel E., or 5-fluorouracil F. for 72 
hours. Cell viability was measured by MTS assay. Fold change over vehicle treated cells was calculated. IC50 values were determined by 
nonlinear regression analysis using a log (inhibitor) vs response (three parameters) model in GraphPad Prism 6.0. The results are presented 
as the mean of three independent experiments performed in triplicate. Error bars are standard deviations.
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Figure 2: Effects of BRG1 inhibitors on breast cancer cell proliferation and viability. A. Cell proliferation was measured by 
MTT assay in three triple negative breast cancer cell lines (MDA-MB-231, MDA-MB-468 and HDQ-P1) with increasing doses of PFI-3 
treatment for 72 hours. B. Cell viability in MDA-MB-231 cells treated with increasing doses of ADAADi was examined by MTT assay for 
48 hours. MTT assays were performed on MDA-MB-231 C., MDA-MB-468 D. and HDQ-P1 E. cells treated with 2 μM ADAADi. Each 
data point represents the mean of 3 independent experiments performed in triplicate. Error bars are standard deviations. *P < 0.05, **P < 
0.01, ***P < 0.001. 
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proliferation rate of other cancer cell lines [44].
The bacterial APH (3’)-III enzyme that encodes for 
aminoglycoside resistance generates a minor product that 
can be chromatographically separated from the known 
3’-phosphoaminoglycoside product as well as from the 
parental aminoglycoside. This product, named ADAADi 
(Active DNA-dependent ATPase A Domain inhibitor), 
inhibits the ATPase activity of the SWI2/SNF2 family 
of ATPases [46, 47]. Enzymes from other families of 
DNA-dependent ATPases showed no or greatly reduced 
sensitivity to ADAADi, and DNA-independent or RNA-
dependent ATPases were not affected [47]. Prior studies 
indicated that ADAADi inhibited BRG1 nucleosome 
remodeling activity in vitro [47]. ADAADi derived 
from different aminoglycosides behaves similarly in all 
tested assays [46]; here we utilized ADAADi derived 
from neomycin (ADAADiN). We tested the ADAADiN 
inhibitor on three triple negative lines: MDA-MB-231, 
MDA-MB-468 and HDQ-P1. ADAADiN significantly 
decreased cell proliferation in these cell lines (Figure 
2B-2E). However, ADAADiN failed to decrease cell 
proliferation significantly in cells with reduced BRG1 
expression (Figure 3A-3B; Supplemental Figure 1B). 
This observation strongly suggests that ADAADiN 
targeted BRG1 in these cells by interfering with its ATPase 
function.
Brahma (BRM) is highly homologous to BRG1 
[25, 48] and can also function as the catalytic subunit of 
mammalian SWI/SNF enzymes in a manner mutually 
exclusive of BRG1 [26]. ADAADiN decreased cell 
proliferation to roughly the same extent as shRNA 
mediated knockdown of BRM (Supplemental Figure 1 and 
2). However, the combination of ADAADiN and shRNA 
targeting BRM further decreased proliferation in a manner 
that is statistically significant and additive (Supplemental 
Figure 2). This finding is in contrast to the results obtained 
for treatment of cells with a combination of ADAADiN 
and shRNA targeting BRG1 (Figure 3) and suggests that 
ADAADiN specifically targets BRG1 in these cells.
ADAADiN treatment increased breast cancer cell 
sensitivity to chemotherapeutic drugs
Since ADAADiN inhibited breast cancer cell 
proliferation, we asked if it could also sensitize cells to 
chemotherapeutic drugs, just as BRG1 knockdown does. 
Following pretreatment with ADAADiN, cells were 
exposed to different doses of the same chemotherapy 
drugs, and cell viability was assayed by MTT assay. 
ADAADiN significantly increased the chemotherapeutic 
sensitivity of MDA-MB-231 and MDA-MB-468 cells 
from 3- to well over 10-fold (Table 1). These data establish 
the concept that chemical inhibition of the BRG1 ATPase 
domain might be used to target BRG1 mediated pro-
survival pathways in breast cancer cells.
ADAADiN blocked induction of drug transporter 
gene expression in response to drug treatment
ABC transporters mediate the efflux of anti-cancer 
drugs and are critically involved in multidrug resistance 
[21, 49-51]; the expression of ABC transporters is up-
regulated in patients after neoadjuvant therapy [52]. We 
first surveyed nine ABC transporter genes to determine 
whether BRG1 contributed to their expression in MDA-
MB-231 cells. The results show that BRG1 contributed to 
the endogenous level of transporter gene expression for 
seven of the genes (Supplemental Figure 3).
Since ADAADiN sensitized breast cancer cells to 
chemotherapeutic drugs, we hypothesized that ADAADiN 
treatment might inhibit the transcriptional activation of 
the transporter genes upon chemotherapy drug treatment. 
From the literature, we identified six instances where 
ABC transporter genes are transcriptionally activated in 
response to one or more of the chemotherapeutic drugs 
used in our study. Each of the triple negative breast cancer 
cell lines were treated with vehicle alone or with one of 
the chemotherapy drugs at the IC50, dose and specific 
transporter mRNA levels were compared to levels present 
in cells exposed to drug plus ADAADiN.
ABCC11 was previously identified as a 5-FU efflux 
transporter that directly confers resistance to 5-FU [53, 
Table 1: ADAADiN significantly increased the sensitivity of MDA-MB-231 and MDA-MB-468 to chemotherapy drugs.
MDA-MB-231 MDA-MB-468
Vehicle ADAADi Vehicle ADAADi
5-fluorouracil 16.9 ± 4.6 μM 4.2 ± 1.1 μM 27.15 ± 5.45 μM 5.22 ± 0.63 μM
Cisplatin 5.4 ± 0.8 μM 0.14 ± 0.03 μM 1.94 ± 0.27 μM 0.37 ± 0.08 μM
Cyclophosphamide 1.45 ± 0.15 mM 0.061± 0.005 mM 0.4 ± 0.02 mM 0.028 ± 0.003 mM
Doxorubicin 68.13 ± 5.11 nM 7.16 ± 1.23 nM 60.3± 4.9 nM 8.12± 3.7 nM
Gemcitabine 166 ± 10.8 nM 59.9 ± 7.2 nM 2.21 ± 0.33 μM 0.42 ± 0.015 μM
Paclitaxel 29.25 ± 7.49 nM 1.35 ± 0.52 nM 20.55 ± 1.95 nM 1.21 ± 0.19 nM
Shown are IC
50
 doses for each drug and cell line.
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Figure 3: ADAADiN-mediated inhibition of triple negative breast cancer cell proliferation and viability is due to 
inhibition of BRG1. A. Cell proliferation was measured by MTT assay after ADAADi treatment, inducible BRG1 knockdown, or both 
in MDA-MB-231 cells. B. Cell proliferation was measured by MTT assay after ADAADi treatment, BRG1 knockdown by siRNA, or 
both in MDA-MB-468 cells. Each data point is the mean from 3 independent experiments performed in triplicate; error bars are standard 
deviations. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 4: ADAADiN blocked drug-induced ABC transporter gene expression in triple negative breast cancer cell lines. 
Bar graphs present relative mRNA expression of specific ABC transporter genes in response to vehicle, the indicated chemotherapeutic 
drug, and the indicated chemotherapeutic drug in the presence of ADAADiN in each of the indicated breast cancer cell lines. Each bar 
presents the mean of 3 independent experiments performed in duplicate; error bars are standard deviations. *P < 0.05, **P < 0.01, ***P < 
0.001. A.-B. 5-FU mediated induction of ABCC11 and ABCC2. C. Cisplatin (Cis) mediated induction of ABCC2. D. Cyclophosphamide 
(CYC) mediated induction of ABCG1. E. Doxorubicin (Doxo) mediated induction of ABCC2. F. Gemcitabine (Gem) mediated induction 
of ABCB1. G.-H. Paclitaxel (Ptx) mediated induction of ABCG2 and ABCB1. 
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54]. We observed up-regulation of ABCC11 expression in 
each of the three triple negative cell lines when treated 
with 5-FU, and this activation was attenuated in the 
presence of ADAADiN (Figure 4A). 
Minegaki et al [55] reported that ABCC2 mRNA 
levels increased in a dose-dependent manner when treated 
with 5-FU. ABCC2 expression was increased more than 
2-fold in all three cell lines when treated with an IC50 
dose of 5-FU. When co-treated with ADAADiN, ABCC2 
mRNA levels were significantly decreased (Figure 4B). 
ABCC2 also mediates cisplatin resistance and this is 
correlated with clinical outcome [56, 57]. In our study, 
cisplatin up-regulated ABCC2 expression by 4-fold in 
MDA-MB-468 cells. Activation in MDA-MB-231 and 
Figure 5: Targeting BRG1 results in increased retention of chemotherapeutic drugs. Radiolabeled paclitaxel or 5-FU were 
incubated with MDA-MB-231 cells expressing a control (Scram) shRNA or shRNA targeting BRG1. A.-B. Cellular uptake was determined 
by scintillation counting after harvested cells were washed repeatedly, counted, and lysed. Results were normalized by cell count. C.-D. 
Drug retention was determined by scintillation counting after cells were pulse-chased and prepared as described in Materials and Methods. 
Each bar presents the mean of 3 independent experiments performed in triplicate; error bars are standard deviations. ***P < 0.001.
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HDQ-P1 cells was less than 2-fold but was nevertheless 
statistically significant. However, the up-regulation of 
ABCC2 in each of the three cell lines was inhibited by 
co-treatment with ADAADiN (Figure 4C). 
The expression of ABCG1 is increased in breast 
cancer patients during neoadjuvant therapy with 
5-fluorouracil-doxorubicin-cyclophosphamide, and 
increased levels of ABCG1 predict poor prognosis [58]. 
ABCG1 expression increased in each of the cell lines 
when treated with cyclophosphamide, while the presence 
of ADAADiN suppressed ABCG1 up-regulation (Figure 
4D). 
Targeting ABCC2 by antisense RNA reduces the 
doxorubicin IC50 value by 12-fold in hepatocellular 
carcinoma cells, whereas overexpression of ABCC2 in 
HEK293 cells enhances doxorubicin resistance around 
8-fold [56, 59]. These results suggest that ABCC2 is 
the efflux transporter for doxorubicin. When the three 
triple negative breast cancer lines were treated with the 
IC50 dose of doxorubicin, it caused a greater than 3-fold 
induction of ABCC2 in MDA-MB-231 and HDQ-P1 
cells, and a modest but statistically significant increase in 
MDA-MB-468 cells. The addition of ADAADiN blocked 
ABCC2 induction in each cell line (Figure 4E). 
ABCB1 is overexpressed in gemcitabine resistant 
pancreatic cells and in side population cells with high 
gemcitabine efflux capacity [60, 61]. In non-small-cell 
lung cancer cells, ABCB1 mRNA levels can predict 
gemcitabine chemosensitivity [62]. Homology modeling 
and docking of ABCB1 showed gemcitabine to be a high-
affinity substrate [63]. In the three triple negative lines 
tested, ABCB1 was strongly induced by gemcitabine 
treatment, but ADAADiN treatment effectively blocked 
its induction (Figure 4F). 
EGFR-mediated overexpression of ABCG2 is 
associated with paclitaxel resistance in drug resistant 
MCF-7 cells [64]. Silencing ABCB1 and ABCG2 by 
nanoparticle-facilitated siRNA in MCF-7 cells increases 
chemosensitivity to paclitaxel [65, 66]. As shown in 
Figure 4G-4H, the expression of ABCB1 and ABCG2 
was up-regulated in each of the three cell lines treated 
with paclitaxel. However, the presence of ADAADiN 
significantly blocked the activation of these genes. In 
summary, ADAADiN treatment blocked the transcriptional 
induction of drug transporters by chemotherapeutic drugs, 
which may contribute to the increase chemosensivity in 
ADAADiN treated cells.
Targeting BRG1 led to an increase in drug 
retention
Altering drug efflux transporter expression 
might change the intracellular concentration of the 
chemotherapeutic drugs. Because of the limited 
availability of radiolabeled versions of the drugs used in 
this study, we used only 14C-5-FU and 3H-paclitaxel to 
test this hypothesis. The uptake of the radiolabeled drugs 
was identical in cell cultures expressing control shRNA 
or shRNA targeting BRG1 (Figure 5A-5B). Subsequent 
analysis of cell cultures that were pulse-chased with 
the drugs showed that BRG1 knockdown resulted in 
increased intracellular retention of the drugs (Figure 5C-
5D). We conclude that BRG1-dependent induction of drug 
transporter gene expression by 5-FU and Paclitaxel results 
in increased intracellular concentrations of the drugs. This 
may explain the increased chemosensitivity of cells that 
express reduced levels of BRG1 or that are treated with a 
BRG1 inhibitor.
Drug treatment increased BRG1 binding at drug 
transporter promoters
SWI/SNF enzymes regulate gene expression 
by altering chromatin structure, and BRG1 binds to 
chromatin at many genes that are actively transcribed 
[30, 32]. We asked whether BRG1 is directly involved in 
the drug-induced transcriptional activation of the tested 
transporters. Binding of BRG1 at transporter genes was 
examined by chromatin immunoprecipitation (ChIP) 
in MDA-MB-231 cells treated with vehicle or with 
individual chemotherapeutic drugs at the IC50 dose, and 
these results were compared to results from cells treated 
with ADAADiN prior to and during induction with the 
chemotherapeutic drug. BRG1 binding sites at transporter 
genes promoters were predicted from BRG1 ChIP-seq 
data deposited for HeLa and K562 cells [67, 68]. 5-FU 
treatment enhanced BRG1 binding at ABCC2 by 3-fold 
and ABCC11 by 2-fold, and ADAADiN had no effect on 
BRG1 binding at these genes (Figure 6A). This result is 
consistent with the idea that ADAADiN inhibits ATPase 
activity but has no effect on the ability of the enzyme 
to bind to chromatin [46]. Cisplatin increased BRG1 
enrichment at ABCC2 more than 3-fold, and co-treatment 
with ADAADiN did not change BRG1 binding (Figure 
6B). Similar results were seen in cyclophosphamide, 
doxorubicine, gemcitabine and paclitaxel treated cells, 
where these drugs significantly increased BRG1 binding 
at target drug transporter genes and ADAADiN showed 
no effect on BRG1 binding (Figure 6C-6F). We were 
unable to examine BRG1 binding at the ABCG2 locus in 
paclitaxel treated cells, as there were no BRG1 binding 
sites identified at this locus in reported ChIP-seq data sets 
in different cell contexts. Overall, chemotherapeutic drugs 
increased BRG1 binding to drug transporter genes, and 
these binding events were not affected by the ADAADiN 
BRG1 ATPase inhibitor.
PFI-3, a compound targeting the bromodomain of 
BRG1, BRM, and PB1 [44] had no effect on proliferation 
of any of the breast cancer cell lines tested (Figure 
2A). This is consistent with recent work of others using 
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different cancer cell lines [44] showing that PFI-3 was 
unable to dislodge BRM from chromatin, either globally or 
at specific gene loci. We performed ChIP assays to address 
whether BRG1 remained bound in the presence of PFI-3. 
Eight transporter genes were examined for the binding of 
BRG1 in proliferating MDA-MB-231 cells. Four of the 
Figure 6: Chemotherapeutic drugs increased BRG1 binding at ABC transporter genes in a manner independent 
of ADAADiN. ChIP was performed in MDA-MB-231 cells treated with vehicle, chemotherapy drug alone or chemotherapy drug in 
combination with ADAADi. BRG1 binding at transporter genes was measured by quantitative PCR using primers listed in Supp. Table 2. 
The bar graphs represent the ratio (enrichment) of BRG1 binding to sequences near the indicated transporter gene in cells treated with the 
indicated chemotherapeutic drug alone or in combination with ADAADi relative to binding in vehicle treated cells. Each bar presents the 
mean of 3 independent experiments performed in duplicate; error bars are standard deviations. *P < 0.05, **P < 0.01, ***P < 0.001. A. 
BRG1 binding at the ABCC2 and ABCC11 genes was analyzed in vehicle, 5-FU and ADAADi plus 5-FU treated cells. B. BRG1 binding at 
ABCC2 was analyzed in vehicle, cisplatin (Cis) and ADAADi plus Cis treated cells. C. BRG1 binding at ABCG1 was analyzed in vehicle, 
cyclophosphamide (CYC) and ADAADi plus CYC treated cells. D. BRG1 binding at ABCC2 was analyzed in vehicle, Doxorubicin (Doxo) 
and ADAADi plus Doxo treated cells. E. BRG1 binding at ABCB1 was analyzed in vehicle, gemcitabine (Gem) and ADAADi plus Gem 
treated cells. F. BRG1 binding at ABCB1 was analyzed in vehicle, paclitaxel (Ptx) and ADAADi plus Ptx treated cells. 
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eight transporter genes tested had BRG1 binding. PFI-3 
had no effect on the extent of BRG1 binding observed at 
any of the loci (Supplemental Figure 4). These data are 
consistent with the prior observation that PFI-3 could 
not displace BRM from chromatin [44] and extend those 
findings by showing that PFI-3 also cannot dislodge BRG1 
from chromatin.
BRG1 expression level correlated with breast 
cancer patient survival
To determine the correlation between BRG1 
expression and breast cancer patient survival, we 
retrieved 7 microarray datasets of human breast cancer 
(GSE1456, GSE2034, GSE2990, GSE3494, GSE12093, 
GSE11121 and Chin et al., combined N = 1339) profiled 
on Affymetrix HG-U133A platform [69-75] from Gene 
Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo) and European Bioinformatics Institute (http://
www.ebi.ac.uk/arrayexpress for Chin et al, 2006 [75]). 
We normalized these datasets using MAS 5.0 software 
in GeneSpring 12.0 (Agilent Technologies, Santa Clara, 
CA), scaled to a mean target intensity of 600, and log
2
 
transformed. 88 samples from GSE2990 were also used in 
GSE3494, and thus excluded from GSE2990. 23 samples 
without survival information and 7 samples with distance 
metastasis-free survival of 0 were excluded, which left 
1221 non-redundant samples for survival analysis. There 
was a negative correlation between BRG1 expression level 
and patient prognosis, in which high levels of BRG1 were 
associated with poor prognosis (Figure 7). This result 
provides independent corroboration of a prior study [27] 
linking BRG1 levels with poor clinical outcomes of breast 
cancer patients. That conclusion, like our analysis of 
patient data here, was not limited to triple negative tumors, 
which make up only about 15% of patient tumors. Future 
studies will need to determine whether specific breast 
tumor subtypes have a negative BRG1 level correlation 
with prognosis. 
Our results show that BRG1 knockdown or 
inhibition increases chemosensitivity and decreases drug-
induced increases in ABC transporter gene expression. 
This suggests that BRG1 overexpression that is normally 
observed in primary breast tumors [27, 33] may result in 
elevated ABC transporter gene expression and possible 
chemoresistance. We might therefore expect that 
transporter gene expression would correlate with BRG1 
expression. The microarray datasets used for correlating 
high BRG1 expression with decreased survival were 
interrogated for expression levels of the transporter genes 
that were stimulated by chemotherapeutic drugs in a 
BRG1-dependent manner (Figure 4). Three of these genes 
(ABCB1, ABCC2, ABCG2) showed increased levels of 
expression that correlated with BRG1 expression, whereas 
one of the genes (ABCG1) showed an inverse correlation 
(Supplemental Figure 5). The fifth gene, ABCC11, was 
not present in the microarray datasets. It is important to 
remember, however, that levels of specific transporter gene 
expression were generated from the combined dataset 
representing patients with a spectrum of breast cancers and 
that the majority of samples were isolated upon biopsy 
Figure 7: High BRG1 expression levels in breast tumors predicts poor patient prognosis. Kaplan-Meier curves of distance 
metastasis free survival of human breast cancer patients from 7 combined datasets were plotted according to the level of BRG1 expression, 
with the 1st quartile having the lowest BRG1 expression designated as “low” and 4th quartile having the highest BRG1 expression designated 
as “high”. The log-rank test was used for statistical analysis.
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prior to any treatment. Nevertheless, this analysis provides 
support for the idea that ABC transporter gene expression 
is linked to BRG1 expression.
DISCUSSION
Small molecule inhibition of the BRG1 ATPase 
domain is a promising therapeutic strategy
Previous work by us and others indicates that BRG1 
is overexpressed in most breast tumors regardless of 
classification and that BRG1 knockdown in triple negative 
breast cancer cells caused a slow proliferation phenotype 
[27, 33]. Here we report that BRG1 knockdown cells have 
increased sensitivity to chemotherapeutic drugs currently 
used to treat breast cancer (Figure 1), suggesting that 
targeting BRG1 may be a viable approach to augmenting 
current therapeutic regimens. 
Delivery to and continued expression of knockdown 
vectors in most tissues and specifically in tumors 
presents significant challenges [76]. Identification of 
small molecule inhibitors, in contrast, has been an 
effective therapeutic approach for decades. PFI-3 is a 
cell-permeable small molecule inhibitor that specifically 
targets the bromodomains of BRG1, BRM, and a third 
mammalian SWI/SNF subunit, Polybromo (BAF180) 
via tight interaction [44, 77]. Bromodomains bind to 
acetylated chromatin and therefore have a targetable 
molecular function [78-80]. A recent study showed that 
PFI-3 treated embryonic stem cells lost stemness and 
deregulated lineage specification. Exposure of trophoblast 
stem cells to PFI-3 markedly enhanced differentiation 
[43]. These results emphasize a key function of the BRG1 
bromodomain in stem cell maintenance and differentiation. 
However, PFI-3, unlike BRG1 knockdown, did not change 
the proliferation rate of triple negative breast cancer cells 
at any concentration (Figure 2A), nor did it displace 
BRG1 from chromatin at specific gene loci (Supplemental 
Figure 4). These results are consistent with a recent 
study indicating that PFI-3 failed to alter proliferation in 
multiple tumor cell types in which BRG1 or BRM was 
mutated or deficient. In that report, the drug was unable 
to displace endogenous BRM from chromatin, suggesting 
at least one reason for its lack of effect [44]. The data are 
also consistent with studies showing that the C-terminal 
portion of BRG1, which includes the bromodomain, was 
dispensable for glucocorticoid receptor-mediated gene 
induction [81] and that the BRG1 ATPase domain, not the 
bromo domain, is required for leukemia cell proliferation 
[82].
In contrast, ADAADiN [46, 47] targets the BRG1 
ATPase domain and in our study decreased breast cancer 
cell proliferation (Figure 2B-2E). The specificity of 
ADAADi for BRG1 in the cells tested was demonstrated 
by two experiments. First, the combination of ADAADiN 
treatment and BRG1 knockdown resulted in an inhibition 
of cell proliferation that was not statistically different 
from either treatment alone. Second, whereas knockdown 
of the BRG1 homologue BRM and ADAADiN treatment 
provided similar inhibition of breast cancer cell 
proliferation, the combination of the two resulted in an 
apparent additive effect on proliferation. This suggests 
that ADAADiN does not or minimally targets BRM 
in these cells. Thus, one or more molecules that could 
simultaneously target BRG1 and BRM might have greater 
potential as a therapeutic agent. Furthermore, ADAADiN 
treatment, like BRG1 knockdown, increased the sensitivity 
of triple negative breast cancer cells to chemotherapeutic 
drugs that are used clinically (Table 1). These results are 
consistent with the observation that the ATPase domain of 
BRG1 is required for GR-mediated transactivation [83] 
and leukemia cell proliferation [82]. In addition, though 
the chemotherapeutic agents used in this study have 
diverse mechanisms of action, none directly target an 
epigenetic regulator, suggesting that combining epigenetic 
therapies with conventional chemotherapies has great 
potential in combinatorial drug approaches to treating 
cancer. Future work will be needed to further explore this 
possibility. Xenografts and animal models could be used 
to probe the efficacy of BRG1 inhibitors. Both in vitro and 
in vivo approaches to understanding differences in BRG1 
functions in normal compared to cancer cells will help 
inform attempts to improve screening or design of new 
inhibitors.
The work presented here supports for the idea that 
targeting BRG1 in breast cancer and in other cancers 
such as melanoma and colorectal, gastric, and prostate 
cancer [84-88] could be therapeutic via mechanisms that 
reduce cell proliferation and increase chemosensitivity. 
Coupled with recent proposals on targeting the BRG1 
homologue BRM in BRG1-deficient tumors [89-92], it 
is apparent that strategies for targeting the human SWI/
SNF enzyme ATPases in context-dependent manners will 
be an expanding area of focus. Indeed, these advances are 
only part of a larger movement demonstrating that broad 
classes of epigenetic regulatory proteins are viable targets 
for novel cancer therapies [93]. 
Regulation of ABC transporter genes by BRG1
Reduction of BRG1 levels or interference with 
BRG1 catalytic function reduces breast cancer cell 
proliferation, and yet these slow proliferating cells are 
more sensitive to cytotoxic agents that preferentially 
target rapidly growing cells. This paradox prompted us to 
investigate BRG1 effects on the expression of transporters 
responsible for drug trafficking in cancer cells. Our data 
show that BRG1 is a regulator of ABC transporters that are 
implicated as efflux transporters for chemotherapy drugs 
[94]. ADAADiN inhibited drug-mediated up-regulation of 
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specific transporter genes, indicating a functional role for 
BRG1. Demonstration that BRG1 was bound to sequences 
near each transporter gene’s transcription start site 
indicates a direct role for BRG1 during therapeutic drug 
mediated gene activation. Together these data suggest a 
possible mechanism for the increased sensitivity of breast 
cancer cells to chemotherapeutic drugs. 
It has been shown that more than half of the ABC 
transporters are involved in drug resistance using the 
NCI60 cell line panel [95]. This redundancy in transporter 
function has limited therapeutic approaches that target 
specific transporters. For example, MDR1 inhibitors such 
as zosuquidar and tariquidar failed in clinical trials despite 
their high potency and specificity [96]. Our discovery that 
catalytic activity of BRG1 is required for the up-regulation 
of multiple ABC transporters in response to drug treatment 
pioneers a new pan-transporter approach to combating 
drug resistance by targeting BRG1. 
MATERIALS AND METHODS
Cell culture
MDA-MB-231 cells were obtained from T. Guise 
[97]. MDA-MB-468 cells were obtained from ATCC. 
HDQ-P1 cells were purchased from DSMZ (Leibniz 
Institute DSMZ-German Collection of Microorganisms 
and Cell Culture, 38124 Braunschweig, Germany. 
MDA-MB-231, MDA-MB-468 and HDQ-P1 cells 
were maintained in DMEM supplemented with 10% 
FBS and Penicillin/Streptomycin. BRG1 knockdown 
by doxycycline-inducible shRNA expression in MDA-
MB-231 cells was performed as previously described 
[33]. siRNA mediated knockdown of BRG1 in MDA-
MB-468 and HDQ-P1 cells was performed using 
reagents and methods previously described [33, 98]. The 
identities of all four triple negative breast tumor lines were 
authenticated by Short Tandem Repeat profiling at the 
Genetic Resources Core Facility, Johns Hopkins School 
of Medicine, Institute of Genetic Medicine.
Reagents
5-FU, cyclophosphamide, gemcitabine, doxorubicin, 
cisplatin, paclitaxel, and 3-(4,5-dimethyl-2-thiazolyl)-2, 
5-diphenyl-2H-tetrazolium bromide (MTT) were 
purchased from Sigma-Aldrich (St. Louis, MO). 
3H-Paclitaxel and 14C-5-Fluorouracil were purchased 
from Moravek Biochemicals (Brea, CA). PFI-3 was 
purchased from Xcess Biosciences, Inc (San Diego, CA). 
ADAADiNN was prepared from neomycin as previously 
described [46]. CellTiter 96 AQueous One Solution was 
purchased from Promega (Madison, WI).
Drug treatment
Cells were plated and incubated overnight before 
treatment with increasing doses of drugs for 72 hours 
to determine the IC50 value. When combined with 
ADAADiN treatment, cells were pre-treated with 2 μM 
ADAADiN for 48 hours and then different drugs were 
added to culture medium at the IC50 value incubated for 
another 24 hours and collected for analysis.
Drug uptake and retention studies
MDA-MB-231 scram and shBRG1 cells were 
treated with doxycycline to induce BRG1 knockdown as 
described previously [33]. Cells were then treated with 
0.1 μCi 3H-Paclitaxel or 14C-5-Fluorouracil for 1 hour or 
6 hours, respectively. Uptake of radiolabeled drug was 
measured after washing the cells repeatedly, cell counting, 
and scintillation counting. For assessing drug retention, 
labeled cells were washed 3 times with PBS to remove 
residual labeling medium and replaced with growth 
medium containing doxycycline and 100 μM paclitaxel 
or 1 mM 5-FU for an additional 2 hours before harvest. 
All cells, including any floating cells, were collected, 
counted and lysed by addition of 0.5 N NaOH. Cell lysates 
were analyzed by scintillation counting. Readouts were 
normalized by cell number.
MTS assay
Cells were seeded in 96-well plates (5,000 cells/
well) overnight prior to drug treatment, and were then 
maintained in the presence of vehicle or drug for 72 
hours before addition of 20 μL CellTiter 96 AQueous One 
Solution per well. Plates were incubated for 2 hours before 
absorbances at 490 nm were measured with a Synergy H4 
Hybrid microplate reader (Bio Tek, Winooski, VT).
MTT assay
Cells were seeded in 96-well plates (5,000 cells/
well) overnight prior to drug treatment, and were then 
maintained in presence of vehicle or drug for 72 hours 
before addition of MTT solution (5 ug/mL). Plates 
were incubated for 4 hours in MTT solution, then the 
media was removed and plates were air-dried. One 
hundred microliters of DMSO were added to each well 
and incubated at room temperature for 30 minutes with 




ChIP was performed as described previously [99] 
with the following modifications: cells were cooled to 
room temperature before being cross-linked with ice-cold 
growth medium containing 3.7% formaldehyde for 40 
min at 4 oC. 50 μg of chromatin extract was used for each 
ChIP with 10 μL of BRG1 antisera or normal rabbit IgG 
(Millipore, Billerica, MA). BRG1 binding at sequences at 
transporter genes was measured by real time qPCR using 
primers listed in Supp. Table. 1.
RT-qPCR
Total RNA was extracted from one million cells 
using RNeasy Plus following manufacturer’s instruction 
(Qiagen Inc., Valencia, CA). cDNA was synthesized 
using SuperScript III kit (Invitrogen, San Diego, CA). 
Gene expression was measured by real time qPCR on a 
StepOne Plus realtime PCR System (Applied BioSystems, 
Grand Island, NY) using the primers listed in Supp. Table 
2. Relative gene expression was normalized to beta actin 
in each sample in experiments comparing vehicle vs drug 
treatment. In experiments comparing scram and shBRG1 
samples, expression was calculated relative to 45S pre-
rRNA.
Survival analysis
Kaplan-Meier survival curves were plotted using 
GraphPad Prism 5.0 software and statistical significance 
was analyzed using the log-rank test.
Statistical analyses
All quantitative data points represent the mean of 
three independent experiments performed in duplicates or 
triplicates with standard deviation (S.D). Unless indicated, 
statistical analysis was performed using GraphPad 
Instat two-tail P value student test (Graphpad Software, 
Inc., La Jolla, CA). The significance of the correlation 
between BRG1 expression and the expression of each of 
the transporter genes was determined by calculating the 
Pearson coefficient. The lines present in the graphs shown 
in Supplemental Figure 5 were determined by linear 
regression.
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